BC Platforms Closes USD $10 million Series B Financing led by Debiopharm and Tesi to accelerate knowledge platform development

Basel, Switzerland, Lausanne, Switzerland and Helsinki, Finland
(ots) - Leading Big Data company developing platform with clinical
and genomic data from 5 million subjects, to transform drug
development and bring clinical benefits to patients.

BC Platforms, a world leader in genomic data management solutions,
today announces that it has closed a $USD 10 million financing round.
The round was led by Debiopharm Innovation Fund in conjunction with
Tesi, a Finnish venture capital and private equity company, and was
supported by BC Platforms' existing investors.

BC Platforms will use the funds to launch new technologies in 2017
integrating complex clinical and genomic data in order to deliver
precision medicine and clinical patient benefits, as well as to grow
its existing genomic data management software business worldwide.

To date, the company has established partnerships with over 50
enterprise level Healthcare units and biobanks globally in 19
countries representing more than 2 million subjects.

BC Platforms' vision is to provide the world's leading analytics
platform for healthcare and industry, with access by 2020 to over 5
million subjects' diverse genomic and clinical data and samples
consolidated from a global network of biobanks. Biobanks are
organized repositories of human biological material and associated
data stored for research purposes. BC Platforms partners with
biobanks to aggregate these data for analysis to provide
transformative solutions for customers across all therapeutic areas
and along the entire product development life cycle.

Tero Silvola, CEO at BC Platforms, said: 'We are delighted to have
been supported by Debiopharm Innovation Fund and Tesi in this new
financing round. This funding will enable us to progress to our next
stage of expansion and to launch our new knowledge based solutions
for R&D customers worldwide. Debiopharm's experience in drug
development will provide us with invaluable insight as we launch this
major new initiative.'

Tanja Dowe, Head of Debiopharm Innovation Fund, said: "We see big
data as a core asset in research and development. We are excited to
have invested in BC Platforms and look forward to working with them
to unlock the potential of big data to dramatically improve R&D
productivity and provide clinical benefits to patients. BC Platforms
fits directly with our fund's vision to invest in innovative
companies that change the way we develop drugs and treat patients.

Joni Karsikas, Investment Manager at Tesi, commented: 'We are
dedicated supporters of innovation and believe that health technology
is going to be a key growth opportunity for Finland. We are very
pleased to be supporting BC Platforms, who are a leader in the field
of genomic data management, in their next stage of transformative
growth.'

About BC Platforms

BC Platforms is a world leader in providing powerful genomic data
management solutions to address some of the biggest healthcare
challenges today by leveraging the convergence of genomics and
healthcare information technologies. Our high performing genomic data
management platform enables flexible data integration, secure
analysis and interpretation of molecular and clinical information. BC
Platforms' vision is to revolutionize decision making in drug
development to bring clinical benefits to patients. Founded in 1997,
the Company has a strong scientific heritage underpinned by 20 years
of working in close collaboration with a network of leading
researchers, developers, manufacturers and vendors.

We currently provide solutions to over 50 leading international
institutions in 19 countries including top-tier academic and hospital
research groups, major pharmaceutical and agricultural companies.
Our management team consists of industry leaders with over 100 years
of combined experience in life sciences, computational biology and
industrial technology. BC Platforms has global operations with its
headquarters in Basel, Switzerland, research and development located
in Helsinki, Finland, and sales and marketing based in London,
Boston, and Vancouver. For more information, please visit
www.bcplatforms.com or follow us on Twitter @BCPlatforms.

About Debiopharm Innovation Fund SA

Part of Debiopharm Group(TM) - a Swiss-headquartered global
biopharmaceutical group including five companies active in the life
science areas of drug development, GMP manufacturing of proprietary
drugs, diagnostic tools and investment management - Debiopharm
Innovation Fund's mission is to invest in companies developing
innovative therapeutics, diagnostics and smart data solutions that
change the way we develop drugs and treat patients. Since 2008, the
company has invested nearly USD 100 million and led 10 out of the 14
last investment rounds in its portfolio companies.

For more information, please visit www.debiopharm.com

We are on Twitter. Follow us @DebiopharmNews at
http://twitter.com/DebiopharmNews

About Tesi (Finnish Industry Investment Ltd)

Tesi (Finnish Industry Investment Ltd) is a venture capital and
private equity company that accelerates companies' success stories by
investing in them directly and via funds. Tesi always invests
together with other investors, providing them with access to high
quality deal flow in Finland. Our investments under management total
1 billion euros and we have altogether 723 companies in portfolio.
www.tesi.fi | @TesiFII

Pressekontakt:
BC Platforms Contact
Tero Silvola
CEO
tero.silvola@bcplatforms.com
Tel. +358 40 590 5733

Debiopharm Innovation Fund SA
Contact
Tanja Dowe
Head of Debiopharm Innovation Fund SA
tanja.dowe@debiopharm.com
Tel. +41 (0)21 321 01 11

Citigate Dewe Rogerson
Contact
Katja Stout
katja.stout@citigatedr.co.uk
Tel. +44 20 7282 1066

Debiopharm Group
Contact
Giuseppe Melillo
Press & Public Relations Officer giuseppe.melillo@consultant.debiopharm.com
Tel: +41 (0)79 271 04 95

Tesi
Contact
Joni Karsikas
Investment Manager
joni.karsikas@tesi.fi
Tel. +358 40 827 0395

Original-Content von: Debiopharm International SA, übermittelt durch news aktuell